KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) EPS (Weighted Average and Diluted) (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed EPS (Weighted Average and Diluted) for 15 consecutive years, with -$1.12 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 205.66% to -$1.12 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.57 through Dec 2025, down 25.07% year-over-year, with the annual reading at $2.56 for FY2025, 25.36% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$1.12 at Halozyme Therapeutics, down from $1.43 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $1.48 in Q3 2021, with the low at -$1.12 in Q4 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.62, with a median of $0.6 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) skyrocketed 575.0% in 2021, then tumbled 205.66% in 2025.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at $0.46 in 2021, then decreased by 8.7% to $0.42 in 2022, then surged by 54.76% to $0.65 in 2023, then skyrocketed by 63.08% to $1.06 in 2024, then crashed by 205.66% to -$1.12 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$1.12, $1.43, and $1.33 for Q4 2025, Q3 2025, and Q2 2025 respectively.